Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone for MDD with Mixed Features
NCT01421134Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Sep 2011
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Lurasidone with Placebo (2 arms). Primary endpoint: Montgomery-Asberg Depression Rating Scale at 6 weeks. Started Sep 2011; status: completed.
02
Drugs
lurasidone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01421134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01421134.